Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2025 | Safety & efficacy of obe-cel in R/R ALL: updated findings from the FELIX trial

Pere Barba • 7 Feb 2025
CAR-T Meeting 2025
Acute Lymphoblastic Leukemia Leukemia CAR-T Obecabtagene autoleucel
FELIX

In this video, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, shares updated results from the FELIX trial (NCT04404660), which is evaluating the CAR T-cell product obecabtagene autoleucel (obe-cel) in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Dr Barba notes the high efficacy of the treatment, with complete remission rates of over 75% and a good safety profile, including low incidence of cytokine release syndrome (CRS) and infections. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting in Strasbourg, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Pere Barba

Future directions for CAR-T in ALL: promising products & strategies being explored 1:11
Future directions for CAR-T in ALL: promising products & strategies being explored
Pere Barba • 7 Feb 2025
Bridging therapy options for patients with ALL & factors influencing bridging therapy selection 0:58
Bridging therapy options for patients with ALL & factors influencing bridging therapy selection
Pere Barba • 7 Feb 2025
Factors clinicians should consider when selecting patients with ALL for CAR-T therapy 1:04
Factors clinicians should consider when selecting patients with ALL for CAR-T therapy
Pere Barba • 7 Feb 2025
Extranodal involvement reveals distinct efficacy outcomes with CAR-T in large B-cell lymphoma 1:28
Extranodal involvement reveals distinct efficacy outcomes with CAR-T in large B-cell lymphoma
Pere Barba • 8 Dec 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals